Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

uniQure Grants Chiesi Select Commercial Rights For The EU’s First Approved Gene Therapy Glybera And Hemo B Gene Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

uniQure has licensed commercial rights covering Europe and select emerging markets to Italy’s Chiesi for first-to-market gene therapy Glybera and a developmental hemophilia B product. The Dutch biopharma is writing the book on pricing and commercialization, regulatory approval, and market access strategy for gene therapy.

You may also be interested in...



Financings Of The Fortnight: IPOs Dominate Early 2014 With 13 Debuts In As Many Days

Insider participation continues to play an important role in getting a majority of biotech IPOs off the ground; and it’s not clear if or when that trend will change. Plus, news on recent financings by Dicerna, uniQure, Lumos Pharma and NightstaRx.

Deals Of The Week Looks At Pricing Conundrums

New therapeutic modalities can bring unexpected challenges in pricing, as uniQure and electroCore learn. Also, deal news from Celgene/OncoMed, Forest/Merck, Theraclone/PharmAthene, The Medicines Company/Rempex and Roche/Molecular Partners.

Chiesi Buys Denmark’s Zymenex For Phase III Enzyme Replacement Therapy

The purchase of Zymenex by Italy’s Chiesi has allowed VC firm Sunstone Capital to reap a second return on its investment in the Danish developer of enzyme replacement therapies.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel